Getwell Oncology is an anti cancer drug manufacturer pharmaceutical company in India. Getwell is one of the oncology products manufacturing companies in India that manufactures world class oncology drugs.
Professional Development – Elevate your knowledge and Skills. Conference attendance inspires, rejuvenates, and energizes delegates. Your participation at our conference will be helpful for a new approach and ideology that can be utilized for the extending the outcome of Companies or Industries. ...
Bortezomib/Velcade is a case study of a company, Millennium, taking a completely new approach to treating cancer and bringing a novel drug, with a new mechanism of action to approval and market launch.BarryGreeneMichaelKauffman
Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, ...
ASCO 2022 will be held in person, making it more attractive for Korean biotech companies that seek to ink partnerships with multinational drugmakers. MedPacto will disclose interim data from a phase 1b study of the combination of vactosertib and FOLFOX, a chemotherapy regimen, in pancreatic can...
“Our first alliance in neurodegenerative diseases has already proven that both companies and teams are united by the same spirit and objectives bringing new and better treatment to patients.” Evotec primarily develops pre-clinical discovery and development platforms. Its portfolio includes a phenotypic...
Pharmaceutical companies have been referring to the 2016 study of the Tufts University to justify the costs of cancer drugs, asreportedon ScienceDirect: “We have conducted the fourth in a series of comprehensive compound-based analyses of the costs of new drug development. In the last study we...
Delta-Fly Pharma wants to make cancer drug development faster, cheaper and more efficient. Using its module technology, the Japanese biotech has bypassed elements of early-stage research to quickly build a broad pipeline of oncology drugs led by a phase 3 leukemia candidate. Now, Delta-Fly is ...
Drug Pipelines 160 Pages June 2024 Global From €2709 €3010 Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2024 Drug Pipelines 50 Pages April 2024 Global From €1505 ASK A QUESTION Google Reviews 4.8 ...
Currently, there are several of companies that hope to bring the potential of TCR-Ts to patients that have not yet benefited from other cell therapies. Loiacono believes that BlueSphere has a unique strategy to bring the development of these therapies to the clinic, de-risking the technology ...